3β-Alkyl-androsterones as inhibitors of type 3 17β-hydroxysteroid dehydrogenase: Inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/ antiproliferative activities on AR+ and ER+ cell lines

Molecular and Cellular Endocrinology

Volumn 248, Issue 1-2, 2006, Pages 225-232

  Ngatcha, Béatrice Tchédam ^a   Laplante, Yannick ^a   Labrie, Fernand ^a   Luu The, Van ^a   Poirier, Donald ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Androsterone; Enzyme; Hormone; Inhibitor; Steroid; Type 3 17 HSD

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1; 17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 2; 17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 5; 17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 7; 17BETA HYDROXYSTEROID DEHYDROGENASES TYPE 3 INHIBITOR; 3BETA BUTYLANDROSTERONE; 3BETA CYCLOHEXYLETHYLANDROSTERONE; 3BETA HEXYLANDROSTERONE; 3BETA PHENYLANDROSTERONE; 3BETA PHENYLETHYL 3ALPHA METHYL O ANDROSTERONE; 3BETA PHENYLETHYLANDROSTERONE; 3BETA PHENYLMETHYLANDROSTERONE; 3BETA PROPYLANDROSTERONE; ANDROGEN RECEPTOR; ANDROSTENEDIONE; ANDROSTERONE DERIVATIVE; ENZYME INHIBITOR; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; PROGESTERONE RECEPTOR; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG; 17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 3; 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3; 3 CYCLOHEXYLETHYLANDROSTERONE; 3 HEXYLANDROSTERONE; 3 PHENYLETHYLANDROSTERONE; 3-CYCLOHEXYLETHYLANDROSTERONE; 3-HEXYLANDROSTERONE; 3-PHENYLETHYLANDROSTERONE; ANDROSTERONE; DRUG DERIVATIVE; HYDROXYSTEROID DEHYDROGENASE; ISOENZYME; STEROID RECEPTOR;

BINDING AFFINITY; CELL ASSAY; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; SYNTHESIS;

17-HYDROXYSTEROID DEHYDROGENASES; ANDROSTERONE; CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; ISOENZYMES; RECEPTORS, STEROID;

EID: 33644909844     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2005.10.023     Document Type: Conference Paper

References (42)

1. J. Adamski, and F.J. Jakob A guide to 17β-hydroxysteroid dehydrogenases Mol. Cell. Endocrinol. 171 2001 1 4
2. S. Andersson, D.W. Russell, and J.D. Wilson 17β-Hydroxysteroid dehydrogenase 3 deficiency TEM 7 1996 121 126
3. J. Asselin, R. Melançon, G. Moachon, and A. Bélanger Characteristics of binding to estrogen, androgen, progestin, and glucocorticoid receptors in 7, 12-dimethylbenz(a) anthracene-induced mammary tumors and their hormonal control Cancer Res. 40 1980 1612 1622
4. É. Bellavance, V. Luu-The, and D. Poirier First inhibitors of the steroidogenic enzyme type 7 17β-hydroxysteroid dehydrogenase Lett. Drug Des. Discov. 1 2004 194 197
5. M. Bérubé, and D. Poirier Synthesis of simplified hybrid inhibitors of type 1 17β-hydroxysteroid dehydrogenase via the cross-methathesis and the Sonogashira coupling reactions Org. Lett. 6 2004 3127 3130
6. + identifies two principal targets for the design of inhibitors Structure 4 1996 905 915
7. A. Gangloff, A. Garneau, Y.W. Huang, F. Yang, and S.X. Lin Human oestrogenic 17β-hydroxysteroid dehydrogenase specificity: enzyme regulation through an NADPH-dependent substrate inhibition towards the highly specific oestrone reduction Biochem. J. 356 2001 269 276
8. W.M. Geissler, D.L. Davis, L. Wu, K.D. Bradshaw, S. Patel, B.B. Mendonca, K.O. Elliston, J.D. Wilson, D.W. Russell, and S. Andersson Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3 Nat. Genet. 7 1994 34 39
9. D. Ghosh, V.Z. Pletnev, D.W. Zhu, Z. Wawrzak, W.L. Duax, W. Pangborn, F. Labrie, and S.X. Lin Structure of human 17β-hydroxysteroid dehydrogenase at 2.20 Å resolution Structure 3 1995 503 513
10. S. Gobec, M. Sova, K. Kristan, and T.L. Rizner Cinnamic acid esters as potent inhibitors of fungal 17β-hydroxysteroid dehydrogenase-a model enzyme of the short-chain dehydrogenase/reductase superfamily Bioorg. Med. Chem. Lett. 14 2004 3933 3936
11. F. Labrie, V. Luu-The, S.-X. Lin, C. Labrie, J. Simard, and R. Breton The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology Steroids 62 1997 148 158
12. F. Labrie, V. Luu-The, S.X. Lin, J. Simard, C. Labrie, M. El-Alfy, G. Pelletier, and A. Bélanger Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease J. Mol. Endocrinol. 25 2000 1 16
13. H.R. Lawrence, N. Vicker, G.M. Allan, A. Smith, M.F. Mahon, H.J. Tutill, A. Purohit, M.J. Reed, and B.V.L. Potter Novel and potent 17β- hydroxysteroid dehydrogenase type 1 inhibitors J. Med. Chem. 48 2005 2759 2762
14. R. Le Lain, P.J. Nicholls, H.J. Smith, and F.H. Maharlouie Inhibitors of human and rat testes microsomal 17β-hydroxysteroid dehydrogenase (17β-HSD) as potential agents for prostatic cancer J. Enzyme Inhib. 16 2001 35 45
15. C. Lévesque, Y. Mérand, J.M. Dufour, C. Labrie, and F. Labrie Synthesis and biological activity of new halo-steroidal antiestrogens J. Med. Chem. 34 1991 1624 1630
16. S. Luo, C. Martel, A. Sourla, S. Gauthier, Y. Mérand, A. Bélanger, and C. Labrie Comparative effects of 28-day treatment with the new anti-estrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact mice Int. J. Cancer 73 1997 381 391
17. S. Luo, C. Martel, G. Leblanc, B. Candas, S.M. Singh, C. Labrie, J. Simard, A. Bélanger, and F. Labrie Relative potencies of flutamide and casodex: preclinical studies Endocr. Relat. Cancer 3 1996 229 241
18. V. Luu-The, Y. Zhang, D. Poirier, and F. Labrie Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition J. Steroid Biochem. Mol. Biol. 55 1995 581 587
19. V. Luu-The Analysis and characteristics of multiple types of human 17β-hydroxysteroid dehydrogenase J. Steroid Biochem. Mol. Biol. 76 2001 143 151
20. V. Luu-The, I. Dufort, G. Pelletier, and F. Labrie Type 5 17β-hydroxysteroid dehydrogenase: its role in the formation of androgens in women Mol. Cell. Endocrinol. 171 2001 77 82
21. R. Maltais, V. Luu-The, and D. Poirier Parallel solid-phase synthesis of 3β-peptido-3α-hydroxy-5α-androstane-17-one derivatives for inhibition of type 3 17β-hydroxysteroid dehydrogenase Bioorg. Med. Chem. 9 2001 3101 3111
22. R. Maltais, V. Luu-The, and D. Poirier Synthesis and optimization of a new family of type 3 17β-hydroxysteroid dehydrogenase inhibitors by parallel liquid-phase chemistry J. Med. Chem. 45 2002 640 653
23. R. Mindnich, G. Moller, and J. Adamski The role of 17 beta-hydroxysteroid dehydrogenases Mol. Cell. Endocrinol. 218 2004 7 20
24. N. Moghrabi, and S. Andersson 17β-Hydroxysteroid dehydrogenases: physiological roles in health and disease TEM 9 1998 265 270
25. R. Neri, K. Florance, P. Koziol, and S. Van Cleave A biological profile of a nonsteroidal antiandrogen, SCH1352 (4′-nitro-3′- trifluoromethyl-iso-butyranilide) Endocrinology 91 1972 427 437
26. H. Peltoketo, V. Luu-The, J. Simard, and J. Adamski 17β- Hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes J. Mol. Endocrinol. 23 1999 1 11
27. T.M. Penning 17β-hydroxysteroid dehydrogenase: inhibitors and inhibitor design Endocr. Relat. Cancer 3 1996 41 56
28. D.E. Pittaway Inhibition of testosterone synthesis in the canine testis in vitro Contraception 27 1983 431 436
29. D. Poirier, F. Labrie, and V. Luu-The Inhibition de la 17β-hydroxystéroïde déshydrogénase de type 3 par des dérivés stéroïdiens: étude exploratoire Méd. Sci. 11 Suppl. 2 1995 24
30. D. Poirier Inhibitors of 17β-hydroxysteroid dehydrogenases Curr. Med. Chem. 10 2003 453 477
31. D. Poirier, H.J. Chang, A. Azzi, R.P. Boivin, and S.X. Lin Estrone and estradiol C-16 derivatives as inhibitors of type 1 17β-hydroxysteroid dehydrogenase Mol. Cell. Endocrinol. 248 2006 236 238
32. D. Poirier, P. Bydal, M.R. Tremblay, K.M. Sam, and V. Luu-The Inhibitors of type II 17β-hydroxysteroid dehydrogenase Mol. Cell. Endocrinol. 171 2001 119 128
33. P. Poyet, and F. Labrie Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate Mol. Cell. Endocrinol. 42 1985 283 288
34. J. Simard, C. Labrie, A. Bélanger, S. Gauthier, S.M. Singh, Y. Mérand, and F. Labrie Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro Int. J. Cancer 73 1997 104 112
35. H.J. Smith, P.J. Nicholls, C. Simons, and R. Le Lain Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers Exp. Opin. Ther. Patents 11 2001 789 824
36. B. Tchédam Ngatcha, V. Luu-The, and D. Poirier Androsterone 3β-substituted derivatives as inhibitors of type 3 17β-hydroxysteroid dehydrogenase Bioorg. Med. Chem. Lett. 10 2000 2533 2536
37. +) cells J. Enzyme Inhib. Med. Chem. 17 2002 155 165
38. Tchédam Ngatcha, B., Luu-The, V., Labrie, F., Poirier, D., 2005. Androsterone 3α-ether-3β-substituted and androsterone 3β-substituted derivatives as inhibitors of type 3 17β-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship. J. Med. Chem. 48, 5257-5268.
39. M.R. Tremblay, and D. Poirier Overview of a rational approach towards inhibitors of 17β-hydroxysteroid dehydrogenase type 1 without estrogenic activity: chemical synthesis and biological evaluation J. Steroid Biochem. Mol. Biol. 66 1998 179 191
40. M.R. Tremblay, R.P. Boivin, V. Luu-The, and D. Poirier Inhibitors of type 1 17β-hydroxysteroid dehydrogenase with reduced estrogenic activity: modifications of the positions 3 and 6 of estradiol J. Enzyme Inhib. Med. Chem. 20 2005 153 163
41. G. Verhoeven Androgens and the testis Verhandelingen-Koninklijke Academie voor Geneeskunde van Belgie 54 1992 299 327
42. P. Vihko, P. Harkonen, P. Soronen, S. Torn, A. Herrala, R. Kurkela, A. Pulkka, O. Oduwole, and V. Isomaa 17β-Hydroxysteroid dehydrogenases - their role in pathophysiology Mol. Cell. Endocrinol. 215 2004 83 88